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AbstrAct
Objective Proton pump inhibitors (PPIs) are among the 
most commonly prescribed drugs. Concerns have been 
raised about a potentially increased risk of gastric cancer 
following long-term use. Our aim is to assess the risk of 
gastric cancer associated with PPI use, taking into account 
underlying indications.
Design This is a population-based cohort study. 
Standardised incidence ratios (SIRs) and 95% CIs were 
calculated to compare the risk of gastric cancer among 
long-term PPI users with the corresponding background 
population, while taking confounding by indication into 
account.
setting Population-based study in Sweden (2005–2012).
Participants This study included virtually all adults 
residing in Sweden exposed to maintenance therapy with 
PPIs.
Exposure/Intervention Maintenance use of PPIs, defined 
as at least 180 days during the study period. Maintenance 
use of histamine 2 receptor antagonist was evaluated for 
comparison reasons.
Outcome measures Gastric cancer (cardia and non-
cardia), and subgroup analysis for gastric  
adenocarcinoma, as defined by the Swedish Cancer  
Registry.
results Among 797 067 individuals on maintenance 
PPI therapy, the SIR of gastric cancer was over threefold 
increased (SIR=3.38, 95% CI 3.23 to 3.53). Increased 
SIRs were found in both sexes and all age groups, but 
were especially increased among PPI users younger than 
40 years (SIR=22.76, 95% CI 15.94 to 31.52). Increased 
SIRs were found for each indication studied, including 
those without an association with gastric cancer, for 
example, gastro-oesophageal reflux (SIR=3.04, 95% CI 
2.80 to 3.31), and those with a supposedly decreased 
risk, for example, aspirin users (SIR=1.93, 95% CI 
1.70 to 2.18). The association was similar for cardia 
and non-cardia gastric cancer. Analyses restricted to 
adenocarcinoma showed similar results to those for 
all gastric cancers. Long-term users of histamine 2 
receptor antagonists, which have the same indications 
as PPIs, were not at any increased risk.
conclusions Long-term PPI use might be an independent 
risk factor for gastric cancer. This challenges broad 
maintenance PPI therapy, particularly if the indication is 
weak.
IntrODuctIOn
Proton pump inhibitors (PPIs), introduced 
in the 1980s, are potent gastric acid suppres-
sors that reduce gastric acidity.1–3 PPIs are 
among the most prescribed drugs globally,4 
used for healing peptic ulcers, counteracting 
gastro-oesophageal reflux, eradicating Heli-
cobacter pylori (in combination with antibi-
otics) and preventing primary or recurrent 
peptic ulcers, for example, in individuals 
exposed to aspirin or other non-steroidal 
anti-inflammatory drugs (NSAIDs) or with 
Zollinger-Ellison syndrome (a gastrin-se-
creting pancreatic tumour). However, it 
has been suggested that long-term PPI use 
increases the risk of premalignant gastric 
lesions (eg, polyps, atrophy and metaplasia) 
and gastric cancer.2 5 6 Gastric acid secretion 
blockage may disrupt the gastric microbiome, 
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Research
strengths and limitations of this study
 ► This is a population-based and nationwide design 
based on contemporary use of proton  pump 
inhibitors (PPIs), resulting in sufficient power to 
assess underlying indications (to assess confounding 
by indication).
 ► To our knowledge, this is the largest study to date 
assessing the association between PPIs and gastric 
cancer.
 ► The findings are standardised for age and sex, which 
are often described the major confounding factors 
in epidemiological studies, and calendar time. Yet 
other confounders could not be taken into account 
because the information was not available for the 
background population.
 ► Exposure information is based on the Swedish 
Prescribed Drug Registry, which is initiated in July 
2005 and has a complete nationwide coverage.
 ► Although this study provides some evidence 
for an association between PPI use and gastric 
cancer beyond gastrointestinal indications of use, 
conclusions considering causality can never be 
drawn based on a single study.
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interfere with nitrosamine formation, cause chronic atro-
phic gastritis and increase gastrin serum levels, which can 
all contribute to gastric cancer development.2 5 7 8 The 
effect of PPI use on the gut microbiome may even be 
more prominent than the effects of antibiotics.9 Among 
three recent meta-analyses on the topic, one found no 
association between long-term PPI use and premalignant 
gastric lesions, based on six randomised controlled trials 
(1789 patients in total).2 The second included an addi-
tional trial (2343 patients in total) and found no evidence 
of gastric tumour development in PPI users with atrophy 
or intestinal metaplasia, while an increased risk of gastric 
hyperplasia was indicated.6 The third, based on 11 obser-
vational studies (94 558 participants), reported a 40% 
increase of gastric cancer among PPI users.5 However, the 
impact of confounding by indication remains unknown. 
The present study aimed to assess the risk of gastric cancer 
in long-term PPI users in a population-based design, while 
taking confounding by indication for such treatment into 
account. For comparison reasons, use of histamine 2 
receptor antagonists (H2RAs), which are used for similar 
indications as PPIs, was also studied.
MEthODs
Design
This was a nationwide Swedish population-based cohort 
study designed to examine the risk of gastric cancer in 
individuals exposed to maintenance therapy with PPIs 
(and to maintenance use of H2RAs), compared with the 
Swedish background population of the same sex, age and 
calendar period (7.1–7.6 million adults).10
Only adults (at least 18 years) without a history of any 
cancer were included. The participants were followed up 
from the first prescription of a PPI (or H2RA) during 
the period 1 July 2005–31 December 2012. The data 
were derived from high-quality and nationwide Swedish 
registries, and information on individuals was linked 
between the registries by means of the unique Swedish 
personal identity number.11 The source cohort included 
all Swedish residents who received at least one dispensed 
prescription of commonly prescribed drugs (listed 
in online supplementary appendix 1) between 1 July 
2005 and 31 December 2014 (with follow-up for cancer 
until 31 December 2012). Informed consent was not 
required.
Patient involvement
The Swedish patient organisation for cancer of the 
oesophagus, stomach, liver and pancreas was involved 
in supporting the present study (www. palema. org). The 
development of the research question and outcome 
measures were informed by patients’ priorities, experi-
ences and preferences. The results will be disseminated 
to study participants by means of patient organisations. 
Patients are thanked in the acknowledgements.
Exposure
The study exposure was maintenance therapy with a 
PPI (or an H2RA) according to the Swedish Prescribed 
Drug Registry, defined as a cumulative defined daily dose 
(DDD) of at least 6 months (≥180 days) during the study 
period (before a potential cancer diagnosis). The DDD 
was the average maintenance dose per day for a drug used 
for its main indication in adults, which follows the WHO 
definition. This cumulative DDD was estimated by adding 
the DDD per package, which takes both the potency and 
the quantity of the drug into account, and is therefore a 
proxy for the duration of the exposure. The Anatomical 
Therapeutic Chemical classification system (ATC) was 
used to identify codes representing PPIs (code A02BC) 
and H2RAs (code A02BA). The participants were divided 
into three mutually exclusive exposure groups: (1) 
PPI users (≥180 days on PPIs and <180 days on H2RAs); 
(2) H2RA users (≥180 days on H2RAs and <180 days on 
PPIs); and (3) PPI and H2RA users (≥180 days on PPIs 
and ≥180 days on H2RAs). These medications were also 
available over the counter in Sweden, but only in small 
packages and at a much higher price per dose.12 Thus, 
maintenance users had their medication prescribed and 
were therefore included in this study.
Outcome
The main outcome was a first episode of any gastric 
cancer according to the Swedish Cancer Registry. Gastric 
cancer was defined by the diagnosis codes C16.0 (cardia) 
and C16.1–C16.9 (non-cardia) in the 10th version of the 
International Classification of Diseases (ICD), and adeno-
carcinoma (dominating histological type) was defined by 
the histology code 096.
confounders
Age, sex and calendar period were adjusted for in the 
design. Confounding by indication was evaluated by 
analysing indications for PPI use separately (see online 
supplementary appendix 2 for ICD and ATC codes): 
gastro-oesophageal reflux disease, Barrett’s oesophagus, 
peptic ulcer disease, Zollinger-Ellison syndrome, gastro-
duodenitis, dyspepsia/disruption of gastric function, H. 
pylori infection, H. pylori eradication (combined with H. 
pylori infection in the analyses), and maintenance use 
(≥180 days) of aspirin or other NSAIDs.
Data sources
Four nationwide Swedish registries, all maintained by the 
governmental National Board of Health and Welfare, 
provided data for the study.
The Swedish Prescribed Drug Registry started on 1 July 
2005, and includes all drugs prescribed and dispensed 
in Sweden. Information from these prescriptions is trans-
ferred for registration monthly.13 This registry is highly 
complete (patient identity data are missing in <0.3% of 
all items),13 and was used to collect data on type of medi-
cation, dates of prescribing and dispensing, and DDD per 
package.
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Figure 1 Flow chart of the construction of the cohort 
exposed to maintenance therapy with proton pump inhibitors 
(PPIs) and/or histamine 2 receptor antagonists (H2RAs).
The Swedish Cancer Registry has at least a 96% complete 
registration of all cancers in Sweden since 1958,14 with 
98% completeness for gastric cancer.15 16 This registry was 
used to identify gastric cancer cases among the cohort 
members and the corresponding background population 
(exact annual numbers were available for the used age 
and sex categories), and to exclude individuals with a 
history of any cancer.
The Swedish Patient Registry has a full nationwide 
coverage for all diagnoses from 1987.11 The registration 
of outpatient specialist care is nationwide since 2001. This 
registry was used to collect information on indications for 
PPI use.
The Swedish Causes of Death Registry has 100% complete-
ness for recording of dates of death since 1952.17 This 
registry was used to collect date of death.
statistical analyses
All analyses were conducted according to a preplanned 
protocol. The risk of gastric cancer was compared 
between the exposed cohort and the entire Swedish back-
ground population of the same sex (male or female), age 
group (categorised as 18–39, 40–49, 50–59, 60–69 or ≥70 
years) and calendar period (2005–2006, 2007–2009 
or 2010–2012). Standardised incidence ratios (SIRs) 
and 95% CIs were calculated by dividing the observed 
number of gastric cancer cases with the expected 
number, accounting for changes in age and calendar 
categories.18 The expected numbers were derived from 
the Swedish Cancer Registry and Statistics Sweden.10 
Follow-up time was calculated from the dispense date of 
the first prescription of PPI (or H2RA) within the study 
period, until death, any cancer or end of the study period 
(31 December 2012), whichever occurred first. Subgroup 
analyses were stratified for sex and age. Stratified anal-
yses were performed for each indication whenever at 
least 10 000 exposed individuals were identified with this 
indication. To assess reverse causality (protopathic bias), 
a sensitivity analysis was conducted excluding all cancer 
cases occurring within 1 year of the start of the study. 
Duration of PPI use was estimated based on the total 
DDD per package prescribed before any cancer diag-
nosis, and was categorised into <1.0 year, 1.0–2.9 years, 
3.0–4.9 years or ≥5 years.
The attributable fraction (AF) and the population 
attributable fraction (PAF) were calculated to estimate 
the proportion of gastric cancer in PPI users and the 
total population, respectively (assuming causality). The 
following formulas were used: AF=(SIR−1)/SIR and 
PAF=p(SIR−1)/(p(SIR−1)+1), where p represents the 
prevalence of PPI maintenance use in the population 
(based on the population size in 2009).10 The χ2 test was 
used to calculate p values.
There were no missing data on exposures, outcomes, 
age, sex or calendar period. When no information was 
available for the indication for PPI use (25.0%), the indi-
cation was considered absent.
rEsults
study participants
In total, 797 067 individuals on maintenance PPI therapy 
were included in the exposed cohort, resulting in 
3 866 836 person-years of follow-up (mean 4.9 years). An 
additional 20 210 individuals had maintenance H2RA 
therapy, and 25 726 had both PPI and H2RA maintenance 
therapy. Figure 1 presents how the study participants were 
selected, and table 1 shows their characteristics. Women 
constituted 58.5% of the PPI cohort, and a majority 
(66.1%) was younger than 70 years. Maintenance therapy 
with aspirin (34.8%) and NSAIDs (30.4%) was the most 
common indication for maintenance PPI use, followed 
by gastro-oesophageal reflux (25.3%), gastroduodenitis 
(13.2%) and peptic ulcer (10.0%). H. pylori was the indi-
cation in 7.3% of all participants, and dyspepsia in 5.5%. 
Barrett’s oesophagus and Zollinger-Ellison syndrome 
were rare indications (<1%) and therefore not eligible 
for separate analysis. A third (33.4%) of the partici-
pants had more than one of the listed indications, and 
were therefore included in more than one indication 
group. Overall mortality was slightly lower among PPI 
users (17.3%) compared with H2RA maintenance users 
(19.4%) (p<0.001), while mortality in patients with gastric 
cancer did not differ significantly (p=0.782).
PPI use and overall risk of gastric cancer
Among all participants exposed to maintenance PPIs, 
2219 (0.28%) developed gastric cancer during follow-up. 
Of these, 1652 (74.4%) had non-cardia gastric cancer and 
1943 (87.6%) had adenocarcinoma (table 1). Long-term 
PPI users were at more than a threefold increased SIR of 
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Table 1 Descriptive characteristics of the study cohort 
exposed to maintenance therapy with proton pump 
inhibitors (PPIs) and/or histamine 2 receptor antagonists 
(H2RAs)
PPIs only
n (%)
H2RAs 
only
n (%)
PPIs and 
H2RAs
n (%)
Total 797 067 20 210 25 726
Sex
  Men
330 885 
(41.5) 8076 (40.0) 9778 (38.0)
  Women
466 182 
(58.5)
12 134 
(60.0)
15 948 
(62.0)
Age (years)
  <40 89 231 (11.2) 1885 (9.3) 1822 (7.1)
  40–49
104 003 
(13.1) 2461 (12.2) 3268 (12.7)
  50–59
155 963 
(19.6) 3971 (19.7) 5878 (22.9)
  60–69
177 606 
(22.3) 4563 (22.6) 6354 (24.7)
  ≥70
270 264 
(33.9) 7330 (36.3) 8404 (32.7)
Calendar period
  2005–2006
446 068 
(56.0)
16 550 
(81.9)
23 066 
(90.0)
  2007–2009
222 257 
(27.9) 2670 (13.2) 2304 (9.0)
  2010–2012
128 742 
(16.2) 990 (4.9) 356 (1.4)
Indications
  Gastro-
oesophageal 
reflux
201 868 
(25.3) 2073 (10.3) 6727 (26.2)
  Barrett’s 
oesophagus 6044 (0.8) 17 (0.1) 172 (0.7)
  Peptic ulcers 79 597 (10.0) 1226 (6.1) 2633 (10.2)
  Zollinger-Ellison 
syndrome 31 (0.0) 0 (0.0) 3 (0.01)
  Gastroduodenitis
104 955 
(13.2) 1321 (6.5) 3695 (14.4)
  Dyspepsia 43 901 (5.5) 649 (3.2) 1664 (6.5)
  Helicobacter 
pylori 58 366 (7.3) 641 (3.2) 2041 (7.9)
  Long-term non-
steroidal anti-
inflammatory 
drug use
241 958 
(30.4) 5012 (24.8) 9628 (37.4)
  Long-term 
aspirin use
277 128 
(34.8) 6533 (32.3) 9929 (38.6)
Number of indications
  0 199 608 
(25.0)
7919 (39.2) 5402 (21.0)
Continued
PPIs only
n (%)
H2RAs 
only
n (%)
PPIs and 
H2RAs
n (%)
  1
330 027 
(41.4) 8487 (42.0)
10 320 
(40.1)
  ≥2
267 432 
(33.6) 3804 (18.8)
10 004 
(38.9)
Gastric cancer
  All 2219 (0.28) 12 (0.06) 62 (0.24)
  Adenocarcinoma 1943 (0.24) 10 (0.05) 54 (0.21)
  Cardia 567 (0.07) 1 (0.00) 13 (0.05)
  Non-cardia 1652 (0.21) 11 (0.05) 49 (0.19)
Years of follow-up
  Total 3 866 836 116 015 163 519
  Mean 4.9 5.7 6.4
Cumulative defined daily dosages, estimated number of 
days
  Median 856 450 1741
  IQR 356–2102 270–990 1043–2732
Mortality
  Total
137 619 
(17.3) 3915 (19.4) 3812 (14.8)
  In gastric cancer 
cases 1473 (66.4) 9 (75.0) 39 (62.9)
Table 1 Continued 
gastric cancer of any type (SIR=3.38, 95% CI 3.25 to 3.53) 
and gastric adenocarcinoma (SIR=3.38, 95% CI 3.23 to 
3.53) (table 2). After excluding early gastric cancers, 
the risk remained increased (SIR=1.61, 95% CI 1.51 to 
1.71). The risk of gastric cancer was highest among indi-
viduals receiving PPI for shorter than 1 year (SIR=12.82, 
95% CI 12.19 to 13.47), but there was also evidence for an 
increased risk up to 3 years of PPI use, yet reduced risks 
for use over 5 years (table 3). The strength of association 
was similar for cardia (SIR=3.55, 95% CI 3.27 to 3.86) and 
non-cardia gastric cancer (SIR=3.33, 95% CI 3.17 to 3.50). 
The risk of gastric cancer was similar in men (SIR=3.65, 
95% CI 3.45 to 3.85) and women (SIR=3.07, 95% CI 2.87 
to 3.28). The SIR was higher in younger ages; PPI users 
younger than 40 years had SIR of 22.76 (95% CI 15.94 
to 31.52), while those who were at least 70 years old had 
SIR of 2.76 (95% CI 2.61 to 2.92) (table 2). The subgroup 
analyses for sex and age showed similar results as the 
overall findings in separate analyses for gastric adenocar-
cinoma, as well as for cardia and non-cardia gastric cancer 
(table 2).
PPI use and risk of gastric cancer stratified by indication
The SIR of gastric cancer was increased in each of the 10 
studied groups of indications for PPI therapy (table 4). 
The highest SIRs were found among participants exposed 
to indications with a known association with gastric 
cancer, that is, H. pylori and peptic ulcer. However, the 
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Table 3 Standardised incidence ratios (SIRs) by estimated 
duration of use and 95% CIs of gastric cancer in all 
individuals exposed to proton pump inhibitors 
Duration Cases (n)/total SIR (95% CI)
<1.0 year 1552 12.82 (12.19 to 13.47)
1.0–2.9 years 2193 2.19 (1.98 to 2.42)
3.0–4.9 years 1098 1.10 (0.91 to 1.31)
≥5.0 years 153 0.61 (0.52 to 0.72)
SIRs were also increased for indications without any such 
association. The SIR for gastric cancer was 3.04 (95% CI 
2.80 to 3.31) for gastro-oesophageal reflux. The SIRs were 
increased also for indications where a decreased risk of 
gastric cancer was expected. The SIR was 1.93 (95% CI 
1.70 to 2.18) among those using PPIs because of aspirin 
use without any other indication. The SIRs were generally 
similar for non-cardia gastric cancer. Regarding cardia 
cancer, higher SIRs than for gastric cancer were found 
for the indications gastro-oesophageal reflux and among 
those exposed to aspirin or other NSAIDs, while the asso-
ciations for H. pylori and peptic ulcer were less strong 
(table 4).
Attributable risk
Of all 5823 patients with gastric cancer diagnosed during 
the study period, 38.1% occurred among maintenance 
PPI users. Based on the overall SIR of 3.38 and a preva-
lence of PPI use of 10.7% among adults, the AF among 
PPI users (AF) was 70.4%, and 20.3% in the total popu-
lation (PAF), assuming causality. Using the lowest SIR 
according to table 4 (SIR=1.41), the corresponding 
proportions were 29.1% (AF) and 4.2% (PAF), respec-
tively. Among individuals younger than 40, the prevalence 
of PPI use was 3.3%, and 37.1% of all 97 gastric cancers 
occurred among PPI users, corresponding to AF of 95.6% 
and PAF of 41.8%.
use of histamine 2 receptor blockers only or PPIs and 
histamine 2 receptor blockers and risk of gastric cancer
There were 12 and 62 cases of gastric cancer among main-
tenance H2RAs users only and both H2RAs and PPIs, 
respectively. The risk of gastric cancer was not increased 
in the H2RA-only group (SIR=0.57, 95% CI 0.29 to 0.99), 
and was moderately increased in the group exposed to 
both PPIs and H2RAs (SIR=2.09, 95% CI 1.61 to 2.69).
DIscussIOn
This study provides some evidence of an increased risk of 
gastric cancer among maintenance PPI users, including 
those who had PPI therapy for indications without any 
positive association with gastric cancer. Increased risks 
were found for both cardia and non-cardia gastric cancer, 
in both sexes and all age groups, although the risk was 
more pronounced in younger participants.
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Strengths of the study include the nationwide and popu-
lation-based design, the valid data on exposures, outcomes 
and indications for PPI use, and the large number of indi-
viduals exposed to maintenance treatment with PPIs. To 
our knowledge, this is the largest study to date on this 
topic,19 and the cohort allowed analyses of differences in 
associations between underlying indications.
The main problems of this study are confounding, espe-
cially by indication, and reverse causality. Confounding by 
indication has been investigated by looking at the different 
indication groups, including groups without no increased 
risk of gastric cancer. Unfortunately, we could not identify 
any underlying indication for 25% of the PPI users and 
39% of the H2RA users. It is likely that clear indications 
were more readily recorded, while use for less rigorously 
diagnosed indications was more prone to be missing. This 
may indicate that PPI users had more severe symptoms 
than H2RA users, as also indicated by the higher propor-
tion of PPI users presenting with multiple indications (34% 
vs 19%). Yet the lack of information on indication should 
not explain the associations for known indications—and 
those groups with no apparent risk factors should be less 
likely to have severe gastrointestinal symptoms. Therefore, 
it was unexpected to still see such increased risks of gastric 
cancer in those groups. Unfortunately, we lacked infor-
mation about some potential confounders, for example, 
dietary factors, obesity, tobacco smoking and alcohol over-
consumption, since these are not collected in the nation-
wide health registries. However, the lack of association 
between H2RAs and gastric cancer argues against bias from 
confounding or selection from lifestyle factors or any other 
unknown factors. Since H2RAs were used for similar indi-
cations as PPIs (yet clearly became less popular), the lack of 
association between H2RAs and gastric cancer supports that 
the association between PPI use and gastric cancer may be 
linked to the PPI medication per se. Yet PPIs clearly became 
the first choice of treatment for most indications for gastric 
acid suppression, with almost 40 times more PPI mainte-
nance users than H2RA maintenance users in Sweden. 
The high prevalence of PPI maintenance use among adults 
(10.7% in Sweden) also means that the large majority with 
recognised risk factors for gastric cancer will have received 
PPI treatment at some point. This clearly hampers assess-
ment of PPI use as an independent risk factor, and this may 
even be a larger problem in other study designs especially if 
indications of use cannot be assessed.
The problem of reverse causality, that is, individuals 
taking PPIs because of symptoms arising from an unde-
tected cancer, should have been reduced by only including 
individuals with at least 180 days (6 months) of cumula-
tive exposure before any cancer diagnosis. In addition, we 
excluded all individuals who had gastric cancer within a 
year after inclusion and also stratified the analyses by dura-
tion of use, which still showed increased risks (respectively 
SIR=1.61 and SIR=2.19 among those with an exposure dura-
tion between 1 and 3 years). These increased risks may not 
be entirely explained by reverse causality and detection bias 
alone—since most cases of gastric cancer are believed to be 
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detected within 1 year after onset of symptoms. There are 
no significant waiting times or socioeconomic differences in 
access to endoscopy in Sweden, and no obvious differences 
were found between tumour stages (potential detection 
bias),20 or anatomical locations between the PPI-exposed 
cohort and the background population (online supple-
mentary appendix 3).
The seemingly decreasing risk estimates with a 
longer duration of use are probably because PPI is benefi-
cial for most individuals with known risk factors for cancer 
(eg, peptic ulcers, H. pylori), yet further research seems 
needed for those on maintenance therapy without gastro-
intestinal indications (eg, aspirin and NSAIDs users).
Although our follow-up should ideally have been longer, 
our maximal follow-up time is 7.5 years, which is remark-
ably longer than all studies included in the two meta-anal-
yses assessing premalignant lesions based on randomised 
controlled trials (6–36 months as maximal follow-up).2 6 
Only two smaller cohort studies had longer follow-up,1 19 
and these were included in the only meta-analysis evalu-
ating gastric cancer risk based on observational studies.5 
We also limited our study to maintenance use, defined 
as at least 180 days of exposure, which is a commonly 
used approach.6 Compliance and over-the-counter avail-
ability of some PPIs (esomeprazole, lansoprazole and 
pantoprazole—only in pharmacy, not in retail sale) may 
have resulted in different actual dosages. H2RAs were 
not available over the counter during the study period. 
Therefore, and because of lack of exposure data before 
the study period, we cannot be certain that the registered 
dosage reflects the actual dosage.
The increased risks of gastric cancer among individuals 
with H. pylori and peptic ulcers were anticipated, since both 
these conditions are risk factors for gastric cancer, but the 
associations were stronger than expected, suggesting an 
additional aetiological role of the PPI use. Importantly, 
there was evidence of a substantially increased risk in 
individuals exposed to conditions not known to increase 
the risk of gastric cancer, including gastro-oesophageal 
reflux. Moreover, increased risks were found even among 
participants without any gastrointestinal indications who 
were exposed only to maintenance treatment with aspirin 
or other NSAIDs, although these drugs are expected to 
decrease the risk of gastric cancer.21 22
The higher risk of gastric cancer in the younger age 
group might be related to a recently described increase in 
atrophic gastritis in Sweden, as a potential consequence 
of the stabilising seroprevalence of H. pylori and increased 
prevalence of overweight and obesity.23 Increasing risks of 
gastric cancer in young populations have been described 
previously, in particular of the diffuse type of gastric 
adenocarcinoma.24 25 Gastric symptoms in this group are 
also often overlooked, leading to a widespread (uncon-
trolled) use of PPIs.25 Additionally, gastric carcinogenesis 
may be accelerated in younger patients (who also have a 
higher likelihood of a family history of gastric cancer),26 
which may in turn contribute to a higher vulnerability to 
PPI’s potentially harmful effects. A further exploration 
into the presence and severity of gastrointestinal risk 
factors, age-specific effects and potential mechanistic 
pathways is warranted.
The difference in the association with gastric cancer 
following maintenance therapy with PPIs and H2RAs 
could be explained simply by the fact that PPIs are more 
potent than H2RAs in inhibiting acid secretion.27 PPIs 
block the gastric proton pumps, while H2RAs compete 
with histamine for the histamine 2 receptors. At recom-
mended dosages, PPIs induce a more profound and 
prolonged acid inhabitation than H2RAs. Moreover, the 
acid inhibition of PPIs also increases over time, while the 
effects of H2RAs fade.27
There are several mechanisms that might explain an 
association between PPI use and gastric cancer. Already 30 
years ago, animal studies showed that profound inhibition 
of gastric acid secretion in rodents induces gastric tumours, 
with secondary overstimulation (hypergastrinaemia) 
leading to enterochromaffin-like cell (ECL) hyperplasia 
as generally accepted mechanism of this carcinogenic 
effect.28 29 ECL differentiation has also been described in 
human gastric carcinomas, particularly in the signet ring 
subtype.30 31 Histopathological changes occur due to the 
blockage of the normal gastric acid secretion, leading to 
hypergastrinaemia that might cause hyperproliferation of 
the gastric mucosa, chronic hypochlorhydria (reduction 
of hydrochloric acid in the gastric juice), chronic inflam-
mation and disappearance of normal mucosal glands and 
their replacement by intestinal glands, and possible gastric 
atrophy.6 Long-term PPI use has also been linked to the 
development of fundic gland polyps.32 All these mucosal 
changes could promote gastric carcinogenesis. The blocked 
gastric acid secretion could decrease physiological defence 
mechanisms against pathogenic bacteria.7 8 Diarrhoea is, 
for example, a well-known side effect of PPI use, which is 
often due to infection with the bacteria Clostridium difficile, 
non-typhoid Salmonella species or Campylobacter jejuni.7 This 
reduced bacterial defence mechanism might, in the long 
term, result in chronic inflammation and eventually gastric 
cancer development. Decreased gastric acidity may also 
result in increased bacterial colonisation, including non-gas-
tric micro-organisms, and a greater number of bacteria that 
produce nitrosamines, which are well-established carcino-
gens of the gastric mucosa.5 33 The impact of these proposed 
underlying mechanisms may also be person-dependent 
and time-dependent, which could explain why PPIs are 
seemingly more harmful in, for example, the younger age 
groups.
The results of a single study, even of this size, cannot 
determine causality. Yet the effect size, consistency across 
indications (especially those not associated with an 
increased risk of gastric cancer), lack of association with 
H2RAs and plausible carcinogenic mechanisms mean 
that maintenance PPI use cannot be dismissed as a poten-
tially independent risk factor for gastric cancer. A higher 
awareness for gastric cancer could potentially be consid-
ered in maintenance users of PPI, especially if known 
underlying risk factors are present. Thus, these findings 
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need confirmation in future investigations, especially 
considering the generalisability of the results to popu-
lations with higher incidence of gastric cancer or other 
distribution of risk factors.
To conclude, this large and population-based cohort 
study provides evidence of a substantially increased risk 
of gastric cancer following maintenance use of PPIs per 
se. The consistency across sexes, age groups and indica-
tion groups, including indications that do not increase 
the risk of gastric cancer, supports the overall finding. If 
confirmed in further research, especially among those 
without gastrointestinal risk factors, these findings chal-
lenge a broad use of long-term PPI use, particularly for 
conditions where the indication is weak.
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